RAMA PHOSPHATES
RAMAPHO · NSE
103.06
-0.59 (-0.57%)
as of 30 Oct 2026 close
Open
104.00
High
104.00
Low
100.00
Prev close
103.65
52w high
217.19
10 Nov 2025
52w low
96.80
23 Oct 2026
VWAP
102.16
Delivery %
50.0%
of volume
Volume 11,002 · turnover ₹11.24 L · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 05 Aug 2022
- Market cap
- ₹365 cr
- ISIN
- INE809A01032
- Series
- EQ
- Listed on NSE
- 05 Aug 2022
- Face value
- ₹5
- F&O
- No
Source: NSE equity master · as of 31 Oct 2026 · market cap = shares (30 Sept 2026 filing) × close
Market cap
₹365 cr
P/B
—
ROE (TTM)
—
Debt / equity
—
P/E (TTM)
—
P/S (TTM)
—
Revenue TTM
—
Net profit TTM
—
Net margin TTM
—
EV / EBITDA
—
Interest cover
—
Revenue growth
—
latest quarter YoY
Profit growth
—
latest quarter YoY
Dividend yield
0.24%
₹0.25 / share · payout —
Standalone · last four quarters to 2026-06-30 · tap a tile for the formula
Daily · NSE EOD
Shareholding · as of 30 Sept 2026
Promoters
75.00%
+0.00 pp QoQ
Public
25.00%
Promoter pledge
13.33%
of promoter shares
FPIs 0.16%
DIIs 0.03%
Mutual funds —
Insurance —
Retail 19.06%
Government 0.00%
26-06
26-09
Promoter share by quarter · source: NSE shareholding filings (XBRL). DIIs include mutual funds and insurers.
Quarterly results · Standalone · latest 30 Jun 2026
filed 24 Jul 2026, 03:26 pm IST| ₹ crore | Jun 26* |
|---|---|
| Revenue | 225 |
| Other income | 1 |
| Total expenses | 203 |
| Operating margin | 14.9% |
| Finance costs | 4 |
| Depreciation | 2 |
| Profit before tax | 28 |
| Tax | 6 |
| Net profit | 17 |
| Net margin | 7.6% |
| EPS (₹) | 4.82 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison